Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole

Simple item page
dc.contributor.authorDempsey, Jacqueline M.
dc.contributor.authorKidwell, Kelley M.
dc.contributor.authorGersch, Christina L
dc.contributor.authorPesch, Andrea M
dc.contributor.authorDesta, Zeruesenay
dc.contributor.authorStorniolo, Anna Maria
dc.contributor.authorStearns, Vered
dc.contributor.authorSkaar, Todd C.
dc.contributor.authorHayes, Daniel F
dc.contributor.authorHenry, N Lynn
dc.contributor.authorRae, James M
dc.contributor.authorHertz, Daniel L
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2020-11-09T18:59:29Z
dc.date.available2020-11-09T18:59:29Z
dc.date.issued2019-06-13
dc.description.abstractAim: This study tested for associations between SLCO1B1 polymorphisms and circulating estrogen levels in women with breast cancer treated with letrozole or exemestane. Patients & methods: Postmenopausal women with hormone-receptor positive breast cancer were genotyped for SLCO1B1*5 (rs4149056) and rs10841753. Pretreatment and on-treatment plasma estrogens and aromatase inhibitor (AI) concentrations were measured. Regression analyses were performed to test for pharmacogenetic associations with estrogens and drug concentrations. Results: SLCO1B1*5 was associated with elevated pretreatment estrone sulfate and an increased risk of detectable estrone concentrations after 3 months of AI treatment. Conclusion: These findings suggest SLCO1B1 polymorphisms may have an effect on estrogenic response to AI treatment, and therefore may adversely impact the anticancer effectiveness of these agents.en_US
dc.identifier.citationDempsey, J. M., Kidwell, K. M., Gersch, C. L., Pesch, A. M., Desta, Z., Storniolo, A. M., Stearns, V., Skaar, T. C., Hayes, D. F., Henry, N. L., Rae, J. M., & Hertz, D. L. (2019). Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. Pharmacogenomics, 20(8), 571–580. https://doi.org/10.2217/pgs-2019-0020en_US
dc.identifier.issn1462-2416en_US
dc.identifier.urihttps://hdl.handle.net/1805/24343
dc.language.isoen_USen_US
dc.publisherFuture Medicineen_US
dc.relation.isversionof10.2217/pgs-2019-0020en_US
dc.relation.journalPharmacogenomicsen_US
dc.sourcePMCen_US
dc.subjectbreast canceren_US
dc.subjectexemestaneen_US
dc.subjectletrozoleen_US
dc.subjectpharmacogenomicsen_US
dc.subjectSLCO1B1en_US
dc.titleEffects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleen_US
dc.typeArticleen_US
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891932/en_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
pgs-20-571.pdf
Size:
514.53 KB
Format:
Adobe Portable Document Format
Description:
Main article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medicine Works
Todd Skaar